![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Galera Nabs FDA Fast Track for GC4419
Galera Nabs FDA Fast Track for GC4419
The FDA has awarded Galera Therapeutics fast track designation for GC4419, a candidate that aims to reduce the severity and incidence of oral mucositis caused by radiation and chemotherapy.
Galera has begun enrollment in a Phase 2b study for head and neck cancer patients that will investigate the ability of 30- and 90-mg doses administered before radiation therapy. The study is expected to enroll 200 patients at roughly 55 sites in the U.S.
Upcoming Events
-
21Oct